The painkiller aspirin will be evaluated as a possible treatment for Covid-19 in one of Britain’s biggest trials, which will assess whether it might reduce the risk of blood clots in people with the disease.
A study of the lungs of people who have died from Covid-19 found persistent and extensive lung damage in most cases and may help doctors understand what is behind a syndrome known as ‘long Covid’, in which patients suffer ongoing symptoms for months.
Anthos Therapeutics is developing next-generation anticoagulants that do not have the bleeding risks that current blood thinners have.
A federal court upheld patent claims regarding Bristol Myers Squibb and Pfizer’s Eliquis, which blocks generic rivals from carving out a share of the market for at least six years.
The National Institutes of Health (NIH) announced plans to launch a “flurry” of large-scale clinical trials for treating Covid-19.
Ahead of a planned Phase III study, Pfizer and Sangamo Therapeutics released follow-up data from its Phase I/II Alta study in hemophilia A that showed an investigational gene therapy treatment provided blood-clotting activity levels for more than one year.
Lonza signed a partnership agreement with Anthos Therapeutics to develop and manufacture an antibody treatment for blood clots.
Recent reports revealed that the infection rates between adults and children were similar since the novel coronavirus hit the world in 2019, but men are more likely to exhibit severe symptoms. The report also highlights the importance of contact tracing to help mitigate infection rates.
Pfizer Inc.’s rheumatoid arthritis drug Xeljanz could increase the risk of blood clots in the lungs and in deep veins, the European Medicines Agency (EMA) said.
The U.S. Food and Drug Administration approved Alexion Pharmaceuticals Inc.’s Ultomiris for the treatment of atypical hemolytic uremic syndrome (aHUS) to inhibit complement-mediated thrombotic microangiopathy for adult and pediatric patients.